Skip to main content
Fig. 3 | The Journal of Headache and Pain

Fig. 3

From: Impact of erenumab on acute medication usage and health care resource utilization among migraine patients: a US claims database study

Fig. 3

Acute medication use – mean number of claimsa in the 183 days before and after erenumab initiation. aUse of non-migraine specific acute medications (NSAIDs, opioids, and barbiturates) required a migraine diagnosis on or before 7 days of the medication claim to proxy migraine-specific acute medication. Negative binomial model with repeated measure was used. CI, confidence interval; ER, emergency room; IPTW, inverse probability of treatment weighting; NSAID, nonsteroidal anti-inflammatory drug; RR, rate ratio

Back to article page